Investigational drug · Phase 2
IBI3002
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Atopic Dermatitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "IBI3002"
First trial start
2026
Feb 6, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IBI3002", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atopic Dermatitis
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "IBI3002" as an intervention, largest first.
- A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic DermatitisPivotal-lookingRecruiting
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT07399067 · 120 participants (planned) · Start Feb 6, 2026 · Primary completion Mar 23, 2027
Drug: IBI3002; Placebo and 1 more · For: Atopic Dermatitis
Sites: Beijing, China
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT06213844 · 52 participants · Start Feb 26, 2024 · Primary completion Jul 22, 2025
Drug: IBI3002; Placebo · For: Healthy Participants; Asthma
Sites: Melbourne, Australia
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT06947408 · 44 participants · Start May 14, 2025 · Primary completion May 11, 2026
Drug: Placebo; IBI3002 · For: Asthma
Sites: Beijing, China
- A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With AsthmaRecruiting
The First Affiliated Hospital of Soochow UniversityAcademic, hospital or other
NCT07015749 · 12 participants (planned) · Start Jun 20, 2025 · Primary completion May 20, 2026
Drug: Placebo; IBI3002 · For: Asthma
Sites: Suzhou, China
The First Affiliated Hospital of Soochow UniversityAcademic, hospital or other
NCT07015762 · 9 participants (planned) · Start Jul 14, 2025 · Primary completion May 20, 2026
Drug: IBI3002; Placebo · For: Atopic Dermatitis
Sites: Suzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Atopic Dermatitis
- AfimkibartRO7790121, RVT-3101Phase 312 trials
Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- barzolvolimabCDX-0159Phase 37 trials
Celldex Therapeutics · Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- CM310Phase 35 trials
Keymed Biosciences Co.Ltd · Atopic Dermatitis, Moderate to Severe Asthma, Chronic Obstructive Pulmonary Disease
- VC005Phase 35 trials
Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.